Low expression of RECK indicates a shorter survival for patients with invasive breast cancer

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1084-1089

  Zhang, Yue ^a   Cheng, Shaoqiang ^a   Zhang, Guoqiang ^a   Ma, Wenjie ^a   Liu, Yang ^a   Zhao, Rui ^a   Zhang, Qingyuan ^a   Pang, Da ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECK PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER TISSUE; CLINICAL ASSESSMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE BREAST CANCER; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861691609     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02265.x     Document Type: Article

References (33)

1. Lee JH, Welch DR Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997; 57: 2384-7.
2. Welch DR, Steeg PS, Rinker-Schaeffer CW Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2000; 2: 408-16.
3. Yang J, Mani SA, Donaher JL et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-39.
4. Vernon AE, LaBonne C Tumor metastasis: a new twist on epithelial- mesenchymal transitions. Curr Biol 2004; 14: R719-21.
5. Itoh Y, Nagase H Matrix metalloproteinases in cancer. Essays Biochem 2002; 38: 21-36.
6. Visse R, Nagase H Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
7. Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Noda M A ras-related gene with transformation suppressor activity. Cell 1989; 56: 77-84.
8. Noda M, Kitayama H, Matsuzaki T et al. Detection of genes with a potential for suppressingthe transformed phenotype associated with activated ras genes. Proc Natl Acad Sci USA 1989; 86: 162-6.
9. Takahashi C, Akiyama N, Matsuzaki T, Takai S, Kitayama H, Noda M Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene. Oncogene 1996; 12: 2137-46.
10. Takahashi C, Sheng Z, Horan TP et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998; 95: 13221-6.
11. Oh J, Takahashi R, Kondo S et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
12. Rhee JS, Coussens LM RECKing MMP function: implications for cancer development. Trends Cell Biol 2002; 12: 209-11.
13. Sasahara RM, Takahashi C, Sogayar MC, Noda M Oncogenemediated downregulation of RECK, a novel transformation suppressor gene. Braz J Med Biol Res 1999; 32: 891-5.
14. Furumoto K, Arii S, Mori A et al. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing cysteinerich protein with Kazal motifs. Hepatology 2001; 33: 189-95.
15. Masui T, Doi R, Koshiba T et al. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 2003; 9: 1779-84.
16. van der Jagt MF, Sweep FC, Waas ET et al. Correlation of reversion-inducing cysteinerich protein with Kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 2006; 237: 289-97.
17. Takenaka K, Ishikawa S, Kawano Y et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected nonsmall cell lung cancer. Eur J Cancer 2004; 40: 1617-23.
18. Song SY, Son HJ, Nam E, Rhee JC, Park C Expression of reversion-inducing-cysteine-rich protein with Kazal motifs(RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 2006; 42: 101-8.
19. Haybittle JL, Blamey RW, Elston CW et al. A prognostic index in primary breast cancer. Br J Cancer 1982; 45: 361-6.
20. Span PN, Sweep CG, Manders P, Beex LV, Leppert D, Lindberg RL Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 2003; 97: 2710-5.
21. Hsu MC, Chang HC, Hung WC HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 2006; 281: 4718-25.
22. Zhang J, Hui R, Liu P, Yu Y, Liu Y, Hao X Clinical pathologic status and expression of tumor markers in 5, 000 Chinese breast cancers. J Clin Oncol 2006 ASCO Annual Meeting Proceedings 2006; 24: 10644.
23. Gialeli C, Theocharis AD, Karamanos NK Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
24. Szarvas T, vom Dorp F, Ergün S, Rübben H Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol 2011; 8: 241-54.
25. Chabottaux V, Noel A Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007; 24: 647-56.
26. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003; 22: 167-75.
27. Takagi S, Simizu S, Osada H RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 2009; 69: 1502-8.
28. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009; 9: 20.
29. Vagima Y, Avigdor A, Goichberg P et al. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J Clin Invest 2009; 119: 492-503.
30. Mook OR, Frederiks WM, Van Noorden CJ The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69-89.
31. Planagumà J, Liljeström M, Alameda F et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol 2011; 42: 57-67.
32. Shen Q, Lee ES, Pitts RL, Wu MH, Yuan SY Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells. Mol Cancer Res 2010; 8: 939-51.
33. Holmbeck K, Bianco P, Yamada S, Birkedal-Hansen H MT1-MMP: a tethered collagenase. J Cell Physiol 2004; 200: 11-9.